Article

Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C.

Université Paris Descartes
Annals of internal medicine (Impact Factor: 16.1). 09/2008; 149(6):399-403.
Source: PubMed

ABSTRACT The effect of regression of cirrhosis in chronic hepatitis C is unknown.
To evaluate the relation between regression of cirrhosis and clinical outcome in patients with chronic hepatitis C after antiviral therapy.
A cohort of patients with cirrhosis treated between 1988 and 2001.
Hepatology unit of a tertiary care center in France.
96 patients with chronic hepatitis C and biopsy-proven cirrhosis (METAVIR score F4) who were treated with an interferon-based regimen and had at least 1 posttreatment liver biopsy. Patients were followed until November 2006.
Occurrence of a combined end point of liver-related events (ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatocellular carcinoma, or liver transplantation) and death in patients with regression of cirrhosis (defined as a decrease from 4 to <or=2 METAVIR units on posttherapy liver biopsy).
The median follow-up was 118 months (interquartile range, 86 to 138 months). Eighteen patients had regression of cirrhosis. The incidence of the combined end point per 100 patient-years was 0 in patients with regression of cirrhosis and 4 in patients without regression of cirrhosis (P = 0.002, log-rank test). The transplantation-free survival rate at 10 years was 100% in patients with regression of cirrhosis and 74.2% in patients without regression of cirrhosis (P = 0.025).
Selection of patients was retrospective; selection and survival biases may have influenced the estimates of the overall rate of regression of cirrhosis. The low number of patients who experienced regression of cirrhosis precludes analysis of factors that could predict regression of cirrhosis.
Regression of cirrhosis occurs after antiviral therapy in some patients with chronic hepatitis C. Regression is associated with decreased disease-related morbidity and improved survival.

0 Followers
 · 
117 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A combination treatment of interferon and ribavirin is the standard and the commonly used treatment for chronic hepatitis C (CHC). Developing noninvasive tests like serum indicators that can predict treatment outcome at an early stage of therapy is beneficial for individualized treatment and management of CHC. A glyco-indicator based on the glyco-alteration of serum α1-acid glycoprotein, LecT-Hepa, was discovered by glycomics technologies as a robust indicator of liver fibrosis. Here, we investigated the clinical utility of LecT-Hepa for evaluation of treatment outcome. Firstly, ninety-seven patients with CHC were used for comparison of LecT-Hepa in serum and plasma. We found no significant difference in the concentrations of LecT-Hepa in serum and plasma. And then, 213 serum specimens from 45 patients who received 48 weeks of treatment with interferon and ribavirin were followed up for 96 weeks, and were used for evaluation of the role of LecT-Hepa. We found that LecT-Hepa might reflect the change in fibrosis regression during the treatment process. Moreover, the change of LecT-Hepa at the first 12 weeks of treatment could already predict the antiviral treatment response, which was more superior to FIB-4 index and aspartate aminotransferase-to-platelet ratio index (APRI) in this study. These results provide a new perspective that serum glycoprotein could be used as a joint diagnosis indicator for estimation treatment outcome of viral hepatitis at earlier stage of therapy.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced due to HCV recurrence after transplant. Interferon-based antiviral treatment administered either prior to or after transplant to prevent or treat HCV recurrence, respectively, is limited due to poor tolerability and low efficacy. However, the treatment of HCV in the transplant setting is changing considerably with the availability of newer direct-acting antivirals and interferon-free regimens. This article will review the experience to date treating HCV in the setting of cirrhosis and LT and will discuss the unique challenges encountered when treating this population. This article is protected by copyright. All rights reserved.
    Liver Transplantation 01/2015; DOI:10.1002/lt.24080 · 3.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Le traitement de l’infection chronique par le virus de l’hépatite C (VHC) a singulièrement progressé ces 2 dernières décennies. Depuis 15 ans environ, la combinaison de l’interféron alfa pégylé et de la ribavirine permettait d’obtenir un taux de réponse virologique prolongée, assimilable à une guérison, chez 45 % des patients infectés par un génotype 1, 65 % de ceux infectés par un génotype 4, 70 % des génotypes 3 et environ 85 % des génotypes 2. Une meilleure compréhension du cycle réplicatif du VHC a permis le développement d’antiviraux directs spécifiques du VHC ciblant les protéines virales (la protéase NS3/4A, la polymérase NS5B avec des inhibiteurs nucléosidiques et non nucléosidiques, la protéine multifonctionnelle NS5A du complexe de réplication). La combinaison d’inhibiteurs de première génération en association avec l’interféron pégylé et la ribavirine a montré une efficacité antivirale élevée (75 % de guérison des génotypes 1) avec une tolérance difficile pour les inhibiteurs de protéases de première génération qui ont fait l’objet d’une autorisation de mise sur le marché en 2011 (telaprevir et boceprevir) et de recommandations d’utilisation chez les patients mono-infectés par le VHC en 2012 et chez les co-infectés VIH/VHC en 2013. Puis des combinaisons d’antiviraux directs de deuxième génération avec l’interféron pégylé et la ribavirine ont permis d’augmenter les taux de guérison de 75 à 90 % et de réduire la durée des traitements, les effets secondaires et le nombre de comprimés. La prochaine étape sera la combinaison d’antiviraux directs qui deviendra le standard de traitement en 2015. Ces excellents résultats obtenus chez des patients « faciles à traiter » et en petit nombre ont été confirmés dans les études de phase III et dans les « populations difficiles à traiter » (en échec de traitements antérieurs, notamment des inhibiteurs de protéases, cirrhotiques, transplantés hépatiques ou rénaux, sujets infectés par le VIH ou chez des patients polymédicamentés avec les risques d’interactions médicamenteuses). Ces progrès uniques dans l’histoire du médicament rendent obsolète tout écrit sur le traitement de l’hépatite C.
    Médecine et Maladies Infectieuses 10/2014; DOI:10.1016/j.medmal.2014.07.015 · 0.91 Impact Factor